Metabolex is working to
commercialize best-in-class treatments for type 2 diabetes,
including the novel insulin sensitizers MBX-102 in Phase 2
development, and MBX-2044, which has completed a Phase 2a trial.
MBX-2982, a compound that targets the G-protein coupled
receptor-119 (GPR-119) to stimulate glucose-sensitive
insulin secretion, is in phase 1 clinical development. |